Pathogenic variants in SFTPA1 and SFTPA2 are also associated with lung malignancy, like in this case, with the risk of lung cancer in this group estimated to be as high as 36% as compared to 13% for individuals with IPF [12]. The gene discussed is SFTPA2; the disease is lung carcinoma.